Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

ABSTRACT: Primary refractory acute myeloid leukemia (AML), or primary induction failure, represents a continued challenge in clinical management. This review presents an overview of primary refractory disease and a discussion of risk factors for induction failure, including current evidence regarding the impact of karyotype and molecular mutation status on responsiveness to chemotherapy. We review the evidence for various treatment options for refractory AML including salvage chemotherapy regimens, allogeneic hematopoietic stem cell transplantation, targeted agents, and non-intensive therapies such as hypomethylating agents. A therapeutic approach to this patient population is presented, and several new and emerging therapies are reviewed.

SUBMITTER: McMahon CM 

PROVIDER: S-EPMC6945493 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature